Mastering Clinical Challenges in IBD

  • Funding Type:
    Professional Development Opportunities
  • Opportunity From:

    MedStar

Opportunity Description:

Read the Brochure 

The incidence of inflammatory bowel disease (IBD) continues to rise in the world, and now affects more than 3.1 million Americans. We currently have a better understanding of the pathogenesis of IBD, allowing for the development of new therapies targeting the inflammatory pathways. Hence, the management of this complex disease is in turn becoming complex, in which the clinician needs to use evidence-based medicine to personalize the use of the appropriate therapy for each individual patient. Becoming familiar with treat-to-target and disease modification strategies is essential to maximize the therapeutic benefit of therapies and the chance of maintaining IBD patients in remission and preventing complications. Patients with long standing IBD carry an increased risk of colon cancer, and the IBD therapies available have potential side effects. It is essential for healthcare providers to use current guidelines in prevention and screening of these complications to maximize patients’ health and the quality of care. IBD not only affects the gastrointestinal tract, but also several extra-intestinal organ systems, often requiring a multidisciplinary approach to the patients involving several medicine specialties, colorectal surgery and radiology as well as nutrition support.

The purpose of this symposium is to provide up-to-date information on the pathogenesis of the disease process, as well as evidence-based recommendations on the management and monitoring of IBD and related inflammatory disorders. Through this course, the gap between state-of-the-art practice and current practices will be closed to provide a high quality, comprehensive, multidisciplinary approach to patients with IBD. We believe this approach will improve the quality of care provided to patients, decrease the risk of complications and morbidity, and reduce the overall burden of IBD on the patient and society. We will be utilizing a novel framework of mentor experts and mentee case presentations during this symposium. We will also be discussing state of the art lectures in training needs, artificial intelligence, and underrepresentation in IBD.

AMA PRA Category 1 Credits™ Physician (5.25 hours), Nurse - ANCC (5.25 hours), Non-Physician Member of the Healthcare Team (5.25 hours), Physician Assistant - AAPA (5.25 hours), Pharmacist - ACPE (5.25 hours), IPCE (5.25 hours), ABIM MOC Part 2 (5.25 hours)